Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 240

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction

Open access
Abelin, Jennifer G., Harjanto, Dewi, Malloy, Matthew, Suri, Prerna, Colson, Tyler, Goulding, Scott P., Creech, Amanda L., Serrano, Lia R., Nasir, Gibran, Nasrullah, Yusuf, McGann, Christopher D., Velez, Diana, Ting, Ying S., Poran, Asaf, Rothenberg, Daniel A., Chhangawala, Sagar, Rubinsteyn, Alex, Hammerbacher, Jeff, Gaynor, Richard B., Fritsch, Edward F., Greshock, Joel, Oslund, Rob C., Barthelme, Dominik, Addona, Terri A., Arieta, Christina M., Rooney, Michael S. · 2019 · Immunity

Abstract

Increasing evidence indicates CD4+ T cells can recognize cancer-specific antigens and control tumor growth. However, it remains difficult to predict the antigens that will be presented by human leukocyte antigen class II molecules (HLA-II), hindering efforts to optimally target them therapeutically. Obstacles include inaccurate peptide-binding prediction and unsolved complexities of the HLA-II pathway. To address these challenges, we developed an improved technology for discovering HLA-II binding motifs and conducted a comprehensive analysis of tumor ligandomes to learn processing rules relevant in the tumor microenvironment. We profiled >40 HLA-II alleles and showed that binding motifs were highly sensitive to HLA-DM, a peptide-loading chaperone. We also revealed that intratumoral HLA-II presentation was dominated by professional antigen-presenting cells (APCs) rather than cancer cells. Integrating these observations, we developed algorithms that accurately predicted APC ligandomes, including peptides from phagocytosed cancer cells. These tools and biological insights will enable improved HLA-II-directed cancer therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2019.08.012

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 240

Metadata

Authors
Abelin, J. G., Harjanto, D., Malloy, M., Suri, P., Colson, T., Goulding, S. P., Creech, A. L., Serrano, L. R., Nasir, G., Nasrullah, Y., McGann, C. D., Velez, D., Ting, Y. S., Poran, A., Rothenberg, D. A., Chhangawala, S., Rubinsteyn, A., Hammerbacher, J., Gaynor, R. B., Fritsch, E. F., Greshock, J., Oslund, R. C., Barthelme, D., Addona, T. A., Arieta, C. M., & Rooney, M. S.
Venue
Immunity
Publisher
Elsevier BV
Published
2019-10
Volume
51
Issue
4
Pages
766-779.e17
ISSN
1074-7613 (ISSN-L)
OpenAlex
W2971621113
Cited by
240
References
29
FWCI
9.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. https://app.cochat.ai/papers/10.1016/j.immuni.2019.08.012
The paper
Abelin, J. G., Harjanto, D., Malloy, M., Suri, P., Colson, T., Goulding, S. P., Creech, A. L., Serrano, L. R., Nasir, G., Nasrullah, Y., McGann, C. D., Velez, D., Ting, Y. S., Poran, A., Rothenberg, D. A., Chhangawala, S., Rubinsteyn, A., Hammerbacher, J., Gaynor, R. B., . . . Rooney, M. S. (2019). Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. Immunity. https://doi.org/10.1016/j.immuni.2019.08.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.